Finance Watch: Aiolos Launches With $245m Series A; OrbiMed’s New Funds Total $4.3bn

Big Rounds Dominate As Quarterly VC Totals Creep Higher

Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D. 

Finance Watch Private Company
• Source: Shutterstock

Venture capital mega-rounds of $100m or more – like the $245m series A round that Aiolos Bio Inc. announced on 24 October – have played a big part in surging quarterly and annual totals of biopharmaceutical company VC financings, even in 2023 when fundraising is down from 2022 despite quarter-over-quarter increases year-to-date.

Biopharmaceutical companies raised $5.8bn in venture capital during the third quarter of 2023, up from $5.6bn in Q2 and $4.9bn...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.